OBJECTIVES: The Carmat bioprosthetic total artificial heart (TAH) contains bioprosthetic blood-contacting surfaces, and is designed for orthotopic cardiac replacement. In preparation for clinical studies, we evaluated the TAH performance and its effects on end-organ function in an animal model.
INTRODUCTION
The Carmat bioprosthetic total artificial heart (TAH) is intended to replace the natural heart in orthotopic position in patients at risk of imminent death from biventricular failure and who are not eligible for heart transplantation. It is designed for placement in orthotopic position, and therefore uniquely fits in the human thoracic cavity. In contrast to the existing pneumatically driven TAH [1] , the Carmat TAH is electro-hydraulically driven, and operates silently. Other differentiating features of the Carmat TAH are its bioprosthetic blood-contacting surfaces and the capacity of the prosthesis to respond automatically to changes in preload and afterload, thereby adapting the blood flow to the patient's needs [2] .
During the development and preclinical validation of the Carmat TAH, several phases of implantation procedures in an animal model have been carried out. The initial animal implantations were done to develop the surgical implant tools and to standardize the surgical and anaesthetic procedures. During the second phase, the animals were kept under anaesthesia to monitor the device performance over 48 h [3] . The objective of the present study was to monitor the safety and performance of the Carmat TAH implanted in calves during the 4-to 10-day follow-up, with the following outcome measures: the absence of haemolytic events, absence of cerebral and renal thromboembolic events and absence of thrombus formation in the ventricular cavities. In parallel, biological and physiological parameters are monitored to verify adequate organ and tissue perfusion.
MATERIALS AND METHODS

Device description
The Carmat TAH is a single-unit device with bioprosthetic blood-contacting surfaces (Fig. 1 ). It contains a left and right ventricle, each with a blood compartment and an activationliquid compartment separated by a hybrid membrane. The membrane consists of processed bovine pericardial tissue on the blood-contacting surface and a polyurethane layer at the liquidcontacting surface. Two electrohydraulic rotary pumps create a systolic and diastolic phase by rapidly reversing the direction of silicon fluid-flow that in turn pushes and pulls the membranes. Pressure sensors in each ventricle provide information on preload and afterload, while ultrasound transducers measure the position of the membranes. An algorithm responds to changes in preload and afterload by adjusting beat rate (35-150 beats per minute) and stroke volume (30-65 ml). The resulting pulsatile blood flow ranges from 2 to 9 l/min, with automated adjustment on the left side to correct for the bronchial circulation. Electronics and microprocessors are contained inside the TAH. CarpentierEdwards® bioprosthetic valves (Edwards Lifesciences, Irvine, CA, USA) located at the inlet and outlet of each blood compartment maintain unidirectional flow. The prosthesis is partially surrounded by a flexible polyurethane compliance bag that contains the actuating liquid. A percutaneous driveline delivers power to the TAH, and retrieves information on device performance. The driveline connects to a console providing uninterrupted power supply and displaying device data and alarms.
Animal model
Twelve Charolais calves weighing 102-122 kg and 2-3 months of age were used for the study. This animal model had been selected for previous studies with the Carmat TAH as was found to be the closest to the human thoracic anatomy. The study was approved by the local animal care ethics committee, and took place at the Biosurgical Research Laboratory of the Georges Pompidou European Hospital in Paris, France.
Anaesthesia
On the day of the surgery, animals were sedated with an intramuscular injection of xylazine (0.1 mg/kg; Rompun® 2%, Bayern Santé Animal, France), repeated intravenously (IV) after placement of a left internal jugular vein catheter. Anaesthesia was induced with diazepam (0.2 mg/kg IV; Valium®, Roche, France) and propofol (1-3 mg/ kg IV; Lipuro® 1%; B-Braun Melsungen, Germany). An alcohol-free propofol formulation was preferred to the similar but alcoholpreserved veterinary formulation, to prevent possible hepatic toxic complication caused by the total intravenous anaesthesia procedure.
The animals were placed in supine position. They were intubated using a straight-cuffed tracheal tube (14 mm external diameter), and mechanically ventilated. Anaesthesia was maintained using propofol (3-7 mg/kg/h IV) and sufentanil (0.5-1 µg/kg/h IV; Sufentanil Aguettant®, Aguettant, France), with atracurium (0.5-1 mg/kg/h IV; Tracrium®, GlaxoSmithKline, France) for muscle relaxation. Prophylactic antibiotics (Cefamandole 30 mg/kg/4 h IV; Céfamandole®, Panpharma, France) were injected during the surgical procedure and the early postoperative phase.
An indwelling arterial catheter was placed to obtain instantaneous blood pressure measurement and repeated arterial blood gases and other laboratory measurements. A pulmonary artery catheter (PAC) was introduced prior to surgery to obtain a reference thermodilution cardiac output measurement under general anaesthesia. During the surgical procedure, the PAC was withdrawn into the superior vena cava for monitoring venous oxygen saturation (SvO 2 ). An oesophageal-rumen tube was passed down to allow drainage of liquid ruminal materials and gas during the procedure.
Preimplant conditioning of the calves improved over time. The stress induced by animal transportation often resulted in bronchial colonization or infection impairing preimplant conditions. We organized animal transport to allow on-site acclimatization for several days in advance, which resulted in stress reduction and the opportunity to administer preventive treatment for potential respiratory tract infection. Following TAH implantation, animals were kept anaesthetized during the first night to ensure minimal motion while invasive monitoring was kept in place to ensure optimal perfusion and to minimize the risk of postoperative bleeding. Chest tubes were removed and sedation was withdrawn typically on the next morning (12 h postoperatively) and sub-cutaneous morphine was provided at regular intervals to control pain. Extubation was carried out as soon as the animal breathed spontaneously and recovered with adequate muscular tonus. Additional oxygen was provided through a tube placed in the animal's snout if peripheral oxygen saturation was <94% or if mucosal coloration appeared suboptimal when we failed to obtain reliable oxygen saturation measurement. Hydration was maintained with IV 5% glucose solutes (30-40 ml/kg/day) and by providing free access to water. Volumes infused were reduced or stopped when the animal drank spontaneously. Blood transfusion was provided as required to keep haemoglobin concentration >8 g/dl.
Surgical procedure
The pericardial space was exposed via a median sternotomy. After systemic administration of heparin (300 IU/kg), a 22-Fr cannula was inserted in the right carotid artery through exposure of the neckline and 36-Fr cannulas were placed in the inferior and superior vena cava. Cardiopulmonary bypass (CPB) was initiated with activated clotting time >400 s. The aortic cross-clamp was placed proximal to the origin of the brachiocephalic artery. The heart was excised 1 cm below the atrioventricular plan and at the aorta and the pulmonary artery distal from their respective valve commissures.
The atrial cuffs, composed of pericardial tissue supported with Dacron and a central opening reinforced with silicon rings, were trimmed to the suitable size, and sewn to the atrioventricular orifices, reinforced with felt strips. A titanium atrial interface was mounted on the silicone rings. After placing the four valves in the right and left inlets and outlets of the TAH' blood compartments, the TAH was secured on the interface via a click-on mechanism (Fig. 1) . The Dacron outlet conduits were sewn end-to-end to the aorta and pulmonary artery, respectively. The percutaneous driveline was tunnelled sub-cutaneously to exit the skin right-laterally. Deairing of the TAH was accomplished by incremental active filling of the device and aortic and pulmonary suction. CO 2 was used to facilitate deairing and to mitigate the risk of air embolism. After unclamping the aorta, the TAH output was gradually increased and the animal was weaned from CPB. Following careful haemostasis and placement of chest tubes, the sternum and skin were closed.
Postoperative care and data collection
Immediately after surgery, the animals were placed in a cage in more physiological abdominal sternal-side recumbency. Extubation was done as soon as the animal was completely awake and with satisfactory spontaneous breathing and deglutition.
Typically, on the first postoperative day, the awake animals were transferred to the animal care facility where careful monitoring was managed by a team of clinicians, veterinarians and technical staff. Haematological values (haemoglobin, platelets, plasma-free haemoglobin), creatinine, bilirubin and lactate levels were measured preimplant, postimplant and daily thereafter. Mean arterial and central venous pressure, central venous oxygen saturation, urine output and TAH blood flow were monitored continuously.
Euthanasia criteria
The calves were euthanized in case of discomfort compromising the animal wellbeing, such as respiratory dysfunction, severe blood loss and cerebral dysfunction. The decision was taken by a committee of two medical experts (surgeon and anaesthetist) involved in the study and an independent veterinarian anaesthetist. To prevent post-mortem clot formation inside the prosthesis, a minimum of 25 000 UI of heparin was injected before induction of euthanasia with pentobarbital IV. Autopsy was performed on all animals, with histological examination of the lungs, liver, brain and kidneys. All devices were inspected for deposits in the blood cavities and on the biological valves, but not disassembled.
RESULTS
Twelve female Charolais calves were implanted with the Carmat TAH between January and June 2013 for 1-10 days (Table 1) . Eight animals were extubated and four were able to stand up, drink water and eat solid food on postoperative day 1. Four animals were kept alive on the TAH beyond the 4-day objective; two survived 4 days, one survived 8 days and one up to 10 days. The two animals surviving 8 and 10 days had recovered their enteral function.
For 6 animals, the postoperative course was restricted to 1 day. One animal (1 in Table 1 ) suffered from irreversible bronchospasm leading to respiratory failure. In another animal (4), there was a right ventricular inflow obstruction. Autopsy showed an overextended right atrial free wall that bulged into the atrioventricular orifice of the prosthesis. Excessive bleeding led to euthanasia on postimplant day 1 in two cases. Autopsy revealed leakage from the aortic conduit suture in one animal (5) and leakage from the pulmonary conduit connection in the other animal (11). One animal (9) had anuria, and was euthanized at postoperative day 1. Autopsy showed acute tubular necrosis. The sixth case that survived only 1 day (animal 6) had an incomplete connection of the atrial interface to the prosthesis, provoking air-entrapment during the weaning procedure and subsequent gaseous embolism and coma. In subsequent cases, markers on the prosthesis body ensure that the prosthesis is positioned correctly, and locked securely onto the atrial interface.
Gaseous embolism was observed in two other animals. In one case (animal 3), this was caused by air leakage at the connection of the atrial interface to the silicon rings that are located at the centre of the atrial sewing cuffs. Following this event, the thickness of the silicon rings was increased to ensure airtight sealing. The other case (animal 8) was due to over-pressure of the CO 2 gas tank. This was a technical issue resolved by adding a flow meter to the tank.
Two animals survived 4 days before being euthanized because of respiratory failure in one case (animal 2) and inability to mobilize due to rear limb ligament rupture in the other case (animal 10). One animal survived 8 days, and died of sepsis and respiratory failure. The longest support duration in this series was 10 days; we suspect that this calf suffered a poly-transfusion reaction syndrome. Consequently to this case, only single-donor blood transfusions were used.
Apart from the 3 animals with air embolism, none of the other animals presented any neurological events. The cumulative support duration for the 12 calves was 37 days.
Laboratory data and haemodynamics
Since most animals were supported for a short duration, an overview of haematological, biochemical and haemodynamical data up to 4 days postimplant is given in Table 2 . Plasma-free haemoglobin ( pfHb) was available for three of the four animals that were supported for at least 4 days (Fig. 2) , with low-normal levels for animal 10 (4-day support) and 12 (8-day support). Animal 7 (10-day support) showed peak levels up to 33 mg/dl, due to polytransfusion haemolysis from multiple donors.
For the two animals supported for 8 and 10 days, platelet counts decreased post-surgery and recovered to preimplant levels after 5-6 days (Figs. 3 and 4) . These figures show a similar pattern for creatinine; elevated in the postoperative phase and returned to normal values after 5-7 days. Serum lactate increased postimplant, and returned to normal values after 3-4 days, but increased again in animal 7, likely related to the poly-transfusion reaction in this case.
TAH blood flow was optimized to 9 l/min in both cases, with 97 and 96% right/left balance to account for bronchial shunt. Continuous pressure monitoring in the animals was constraint by the indwelling catheters, which were removed early to facilitate animal mobility and avoid potential catheter disconnection. The mean arterial pressure was 90-110 mmHg in both cases. Central venous pressure and left atrial pressure averaged 20 mmHg in animal 7 and below 10 mmHg in animal 12. Mean pulmonary artery pressure was measured only preoperatively, and was 20 mmHg in both cases. Postimplant measurements were not done because we did not attempt to place the PAC through the TAH and because direct pulmonary artery punctures before sternal closure carried a risk of postoperative bleeding.
Autopsy findings and histopathology
At necropsy, all animals had variable degrees of pulmonary and visceral oedema. Of the three animals that were comatose due to gaseous embolism, one had cerebral oedema/congestion and brain necrosis with disseminated ischaemic damages, whereas the other two had no macroscopic or histological damage. Macroscopic and histological brain examination of the other nine animals showed no visible infarction, no thromboembolic lesions or haematoma and no inflammation.
Renal histology confirmed proximal tubular necrosis in one animal suffering from anuria and isolated cortical infarction in two animals. Another animal (8-day survivor) had bilateral haemorrhagic kidney infarction, related to septicemia. Renal histology of the remaining eight animals showed absence of infection or infarction, with normal parenchyma.
Inspection of the explanted devices showed no thrombus adhered to the inside of the ventricular cavities, atrial suture areas or in the arterial conduits. There were thin fibrin deposits on the expanded polytetrafluoroethylene surfaces of the ventricles, on the bioprosthetic pericardial surfaces and on the valves' leaflets. Endocarditis was present in several animals, with pulmonary embolism related to endocarditis in two cases.
DISCUSSION
Twelve calves were implanted with the Carmat bioprosthetic heart of which four animals were supported for 4, 4, 8 and 10 days, respectively. The device functioned without failure, and produced a pump output ranging from 7.3 to 10 l/min, sufficient to maintain adequate mental status and systemic organ perfusion and function. Extensive digital modelling of the Carmat TAH in combination with cadaver fit studies has resulted in optimization of the device shape in orthotopic position in the human. For example, the distance between the two blood-inflow ports and the plane of each port is designed to enable unrestricted inflow from the left and right atria orifices and the blood outflow ports are directed in angles that follow the position of the human aorta and pulmonary artery. This unique shape of the device poses a challenge for implantation in calves, which generally have a V-shaped thoracic cavity rather than the rounded cavity in humans.
Deairing of the device has been a challenge at the beginning of the study. The rigid structure of the device does not allow squeezing it to mobilize bubbles trapped in the ventricular cavities. Also, since the ventricles are embedded in the device body and surrounded by encapsulated electronics, the inside of the device cannot be checked visually during the deairing. The absence/presence of air embolism was verified by echo. We have improved the deairing procedure by placing open vents in both outflow conduits, progressive mobilization of the intraventricular membranes and systematic use of CO 2 .
The Charolais calves were selected for our study because of the anatomical compatibility of the thoracic cavity/pericardial space. The calves were 2-3 months of age and weighted 102-122 kg, which were both younger and heavier than those recommended in other studies [4] . The native cardiac output at rest in calves of this age range is 12-15 l/min, which is beyond the device capacity designed for human use. This may lead to flow-limited pathology such as pulmonary and visceral oedema observed at necropsy. A contributing factor to visceral oedema might be the frequent rumen bloat in these young animals, which can compress the vena cava and impede venous return. At this early age, calves are incompletely weaned from lactation and this could contribute to the observed digestive disorders. The implant was done through a mid-sternotomy in dorsal position to reproduce the surgical procedure for humans, in contrast with other animal studies where a lateral thoracotomy was performed [5, 6] . A technical reason for the mid-sternotomy was to allow a direct vision for adequate positioning of the atrial sewing cuffs and to prevent inflow obstruction, which has been an issue with a different single-unit TAH [7] . Also, the fact that the prosthesis is 'hinged' on the left side of the atrial interface (Fig. 1) before being clicked onto the interface requires sufficient space for this manoeuvre.
The prolonged unnatural dorsal position during the surgical procedure resulted in compression of visceral organs and of the inferior vena cava, causing venous congestion. The midsternotomy approach likely contributed to the delayed recovery and the increased risk of sternal infection. The natural sternal recumbence of resting calves facilitated scar/skin abrasion on the floor. The mid-sternotomy and prolonged dorsal position have thus been limiting the ability for recovery of the animals. One of the design objectives of the Carmat TAH was to develop a device with biocompatible blood-contacting surfaces, similar to those used for bioprosthetic heart valves, to potentially reduce the need for anticoagulation [8] . Knowing that long-term support would be a challenge with this animal model, we have chosen to test the early postoperative haemocompatibilty of the bloodcontacting surfaces by avoiding any type of anticoagulation. Renal infarction was observed in three animals. In one case, an isolated infarction of the arcuate artery was attributed to gaseous embolism that occurred during the deairing process, for a second animal the origin could not be confirmed. A third animal had bilateral haemorrhagic infarction that was attributed to a septic state. During these short support durations, we did not observe haemolytic events induced by the device nor thrombus depositions inside the blood cavities of the device after explant. Device-related cerebral thromboembolism was not observed by brain histology. These early postoperative findings support the potential haemocompatible properties of the Carmat TAH. Haemocompatibility of the Carmat TAH was assessed previously during in vitro studies [2] . Exposure of circulating human blood to the blood-contacting surfaces demonstrated limited fibrin consumption and platelet adhesion, and minor blood cell depositions on the surfaces. This, together with the animal trial results, led to guidelines for the clinical study of the Carmat TAH that include the use of unfractionated heparin in the early postoperative phase with conversion to anti-vitamin K (international normalised ratio: 2.0-3.0) and acetylsalicylic acid 75 mg.
The assessment of biological reliability (i.e. the device-patient interface) of mechanical circulatory support/replacement during preclinical testing remains a challenge [8] . Findings from preclinical testing in animal models may not be clinically relevant to the experience in humans and clinical problems may arise after device implantation that were not anticipated or signalled by preclinical testing [4, 9] .
In a recent statement paper, endorsed by US cardiology and surgery professional societies, it was concluded that animal models to date have been inadequate in answering questions pertaining to what occurs at the device-patient interface or what types of use and daily activities may promote device failure [10] . The philosophy of the engineering and clinical team involved with the development of the Carmat TAH has been in line with this statement [9] . The TAH performance and reliability have been tested by digital simulations and on haemodynamic benches. The results of these tests in combination with the limited animal experience presented here have led to regulatory approval in France for a clinical feasibility study of the Carmat TAH limited to 4 patients; the first-in-human implant took place in December 2013.
In summary, the Carmat bioprosthetic TAH provided adequate blood flow to organs and tissues in calves implanted up to 10 days. The postoperative recovery has been hampered by constrains of the animal model. This short-term experience suggests that the TAH might have haemocompatible properties, and might be effective as a cardiac replacement device for patients with endstage biventricular failure.
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Dr Latremouille: I would say there are probably both. First of all, as you know in this kind of heart you have a huge diastolic depression, of course, we control that. As well as this, we were using CO 2 , and in one animal out of three we had some problem with the manometer, which give two very important outflows in CO 2 and leading to air embolism. But, as you can see, that is the raw data, and we report all our animals without any selection.
Finally I would like to say that there was a discussion for us to work with the left vent or left vent light, who were in the left atria, and probably we stopped to use the left atrial vent, because at the end of the period of the de-airing process, the depression through the left vent could be discussed too, and we didn't use it no more.
Dr Dellgren: My final question considers the design of the study. Clearly, investigating hemocompatibility during the first days after device implantation is hampered by coagulopathy and bleeding, and you may question whether or not the study can capture any thromboembolic events. In order to capture thromboembolic events, would you now after performing this study and having gained further experience prefer the current model but only including animals, say, after four days, or would you prefer another animal model?
Dr Latremouille: I want to say we were discussing this approach and specifically with our French regulatory affairs to be sure what we can do and what we can't do, and they asked us about the clinical aspect. There was a technical approach. I don't want to speak about that, so it's clear for that. But on the clinical approach they asked us for results over four days without any haemolysis, any stroke, and any thromboembolism in the device. And that is the reason why according to the difficulty of the model we were clear with that and with regulatory affairs in this type of model. We know that, of course, we wanted to go longer, another third or 30, but in the animals that is the only thing. Also we must keep in mind, that in the clinical approach, the approach is only for patients at the end stage failure with a life expectancy probably less than two months. Dr G. Gerosa (Padova, Italy): You have presented data regarding the chronic animal model, but to the best of my knowledge, so far you have already done two human implants. Are you allowed to communicate some data on those human implants? Can you elaborate on that?
Dr Latremouille: First of all, as you know, we did the first implantation last December in an old patient who was 76, and the running of the device was perfect until day 74, and the patient died in this period. The second implantation took place on the 4th of August, and we are now at day 69 after implantation with a younger patient of 68 years of age, and he is perfectly well and he is performing six-minute walking tests regularly and increasing his performance in the exertion for the measurement of reserve.
Dr M. Siepe (Freiburg, Germany): One of the drawbacks of the existing total artificial heart is the external components. What about the external components of your total artificial heart? Is it more convenient for the patient?
Dr Latremouille: I did not have enough time to discuss this in any detail, but the first thing, as you know, it is hydraulic. So, first of all, you don't have any noise, which is quite important for the quality of life, and something which was very important for us, it was a reason to choose a tissue valve to avoid any noise, too.
The second thing about the components we have, the energy supply is through a line which goes through the skin, as usual, and all the electronics are completely embedded inside the device.
Finally, for the moment we have a hospital console near the patient, and we have a wearing belt, which will be available in a couple of days after the authorisation of the French regulatory administration. This is now completely okay.
